Companies/Harvard Bioscience, Inc.

Company profile

Harvard Bioscience, Inc.

NASDAQ: HBIO · Healthcare · Medical - Instruments & Supplies

PublicHQ Holliston, MACIK 0001123494Reports USD

#360 of 1,394 Healthcare companies by revenue33rd-percentile growth

EA Score

58C

FH 46DQ 76GM 49SS 72

v0.1 · 65/100 weight · provisional

↑ disclosure history, growth stability · ↓ return on equity, 3-yr revenue growth

Methodology →

Revenue TTM

$85.5M

Rev growth YoY (TTM)

-6.4%

Net income (FY)

-$56.7M

Employees

331

Market cap

$27.7M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$86.5M$86.5M2025

Net income-$56.7M-$56.7M2025

Operating income-$48.6M-$48.6M2025

Total assets$80.1M$80.1M2025

Liabilities$66.3M$66.3M2025

Equity$13.7M$13.7M2025

Revenue trend

FY2019 – FY2025 · USD

$27.4M

FY19

$116.2M

FY19

$102.1M

FY20

$118.9M

FY21

$113.3M

FY22

$112.3M

FY23

$94.1M

FY24

$86.5M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Instruments, Equipment, Software, and Accessories90%

Service, Maintenance, and Warranty Contracts10%

By geography

UNITED STATES45%

EMEA31%

CHINA13%

Asia, Other8%

Americas, Other4%

The read

Harvard Bioscience, Inc. booked $86.5M in FY2025 revenue, contracting 8.1% year over year — slower than 67% of Healthcare companies we track, at a -65.5% net margin.

Peers · Healthcare

Rein Therapeutics Inc.36D Telescope Innovations Corp.——SCYNEXIS, Inc.61C Cryo-Cell International, Inc.63C

Key facts

CEOJohn D. Duke

SectorHealthcare

IndustryMedical - Instruments & Supplies

HeadquartersHolliston, MA

ExchangeNASDAQ: HBIO

Employees331

IPO date2001-03-19

Latest filings

8-K2026-06-02 8-K2026-05-12 10-Q2026-05-12 8-K2026-05-12 DEF 14A2026-04-21 8-K2026-03-17 10-K2026-03-13 8-K2026-03-12

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.